10 Biggest Antidepressant Drug Companies In 2017
The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide.
Alkermes Plc. (ALKS)
Market is closed
News
- First
- << Previous
- 41 - 50
- Next >>
Here's What Mott Capital Management Thinks About Netflix, Alkermes, Vodafone & More
Mott Capital Management was founded in 2014 by Michael J. Kramer.
Mott Capital Says Netflix (NFLX) At Forefront of Paradigm Shift, Talks Disney, Hain, NXPI Deal, More
Michael Kramer's Mott Capital just released its Q4 letter to investors, which discussed the fund's trying 2016 and some of its portfolio moves during the fourth quarter of last year.
Alkermes Plc (ALKS): Are Hedge Funds Right About This Stock?
We at Insider Monkey have gone over 742 13F filings that hedge funds and prominent investors are required to file by the government.
Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point's Bet on Healthcare Sector Paid Off?
Opus Point Partners Management is a New York-based fund led by Michael S. Weiss and Lindsay A. Rosenwald.
AbbVie Inc (ABBV), Alkermes PLC (ALKS): Will Woodford Investment's Long Positions Rule the Market Again in Q4?
Woodford Investment Management is a London-based hedge fund founded in 2016 by Neil Woodford. At the end of the June quarter, Woodford managed a public equity portfolio valued at $2.13 billion.
Reynolds American, Inc. (RAI), MGP Ingredients Inc (MGPI), and More: Here's What Analysts Had To Say About These Stocks in the Spotlight
Given that analysts can often affect short term sentiment, we at Insider Monkey have put together a list of recent Wall Street analyst commentary concerning five stocks, Reynolds American, Inc.
Why Traders Are Buzzing About Qualcomm, NXP, Alkermes, Cerecor, and More
In this article, we'll examine the associated reasons why QUALCOMM, Inc.
A Look At Recro Pharma Inc (REPH) and Alkermes Plc (ALKS)’s Topline Triumph
Recro Pharma Inc (NASDAQ:REPH) is up more than 27% on Wednesday after announcing data from its lead acute pain trial.
Hedge Funds Regret Buying These Stocks in Q4
Hedge funds are able to charge their clients high fees because of their ability to deliver superior returns and outperform benchmarks.
- First
- << Previous
- 41 - 50
- Next >>
Billionaire Hedge Funds
